Mydecine announces an LOI to co-develop its own digital therapeutics platform, in partnership with Maya Health.

2021 was two different “years” for the psychedelic drug industry. Impressive progress in drug R&D and clinics; stocks pushed down to absurdly lean multiples.

MINDCURE moves an important step closer to the full commercial deployment of its iSTRYM digital therapeutics platform, and also makes a key addition to its management team.

Compass Pathways has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI), tracking the performance of NASDAQ biotechnology/pharmaceutical companies.

MindMed’s Phase IIa clinical trial of LSD for adults ADHD is officially underway, enrolling patients.

Awakn Life Sciences reports its Q3 for fiscal 2021. Highlights include key IP and clinic acquisitions, and the company’s first revenues.

HIPAA compliance certification is the next step for the Company in working towards having the iSTRYM technology platform classified a ‘Software as a Medical Device’ by the FDA.

The ongoing and worsening mental health crisis in the U.S. military is a national tragedy and a national disgrace. Part I reveals the ugly Big Picture.

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) announces the appointment of Doron Sagman, MD, FRCPC, as the Company’s new Chief Medical Officer (“CMO”)

atai partner, Recognify Life Sciences, reports positive Phase 2a results in treating Cognitive Impairment Associated with Schizophrenia.